Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that serum Anti-mullerian hormone (AMH) levels are significantly elevated in women with polycystic ovary syndrome and can serve as a useful biomarker for diagnosis, especially when ultrasonography is unavailable.

This case report describes a 54-year-old Saudi woman with systemic lupus erythematosus and severe alopecia, where conventional treatments were ineffective. When belimumab was ineffective, baricitinib led to significant improvement in her condition, suggesting further research is needed to evaluate baricitinib's role in managing SLE.

This study found that anti-Müllerian hormone (AMH) showed high sensitivity and specificity as a diagnostic marker for polycystic ovary syndrome in the studied population, suggesting its promise as an objective diagnostic tool.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This study found that TPA was significantly more effective than mezerein in inducing dark basal keratinocytes in mouse skin, which may be important in early tumor promotion stages.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

In this retrospective study of patients with advanced Merkel cell carcinoma responding to immunotherapy, those treated for 18 months or longer showed better progression-free outcomes compared to shorter treatment durations, indicating potential benefits of extended therapy duration.

Bimekizumab quickly improves psoriasis symptoms and skin at the molecular level.

This review of the Motherisk Program's counseling experience found a scarcity of information on medication safety related to paternal exposure to drugs and chemicals during the peri-conception period, emphasizing the need for further research.

In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.

This case report describes a 19-year-old patient with microsatellite stable adrenocortical carcinoma who showed a promising 36-month response to pembrolizumab, including structural and biochemical improvements, with primary adrenal insufficiency as a major side effect.

Mycophenolic acid may help hair grow by activating pathways important for hair growth.

This phase 2a trial evaluated Samcyprone for common wart treatment and found that while a sensitization reaction is necessary for therapeutic response, its level does not predict wart clearance.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

Panitumumab can cause excessive ear hair growth.

This study explored the molecular mechanisms by which Polygonum multiflorum may treat androgenic alopecia, suggesting it influences cell apoptosis and inflammation through specific pathways, with potential application value pending further testing.

This study found that BAMO acupuncture combined with Simiao pill can help restore normal prostate tissue structure in mice by reducing DHT production, promoting apoptosis, and decreasing inflammatory responses.

In this study of pediatric melanocytic lesions, researchers at Massachusetts General Hospital observed no concurrent BAP1 loss and BRAFV600E positivity, characteristics of adult BIMT, suggesting that these tumors may develop at a later age rather than in childhood.

This case report describes regression of hidradenitis suppurativa lesions in two patients after 16 weeks of adalimumab treatment.

This study found that belimumab helped achieve low disease activity in over 40% of systemic lupus erythematosus patients in real-life settings, alongside reduced corticosteroid use and fewer flares.

This study found that mirex and TPA promote papilloma formation in CD-1 mouse skin through distinct populations of mutant Ha-ras cells, resulting in additive tumor yields.

This study investigated the health-related quality of life in individuals with androgenetic alopecia before and after photobiomodulation sessions, but the results of the assessment are not reported in the abstract.

This study identified a new gene, mrp4, in mice, which suggests it may have a unique role in the growth and development of hair follicles in the ears and tails.

This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo.

This case report highlights the potential benefits of unilateral adrenalectomy in treating primary bilateral macronodular adrenal hyperplasia, noting a high rate of remission and low risk of recurrence.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

The new treatment was safe and may effectively treat male pattern hair loss.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This study of photobiomodulation therapy devices for androgenetic alopecia found variable improvements in hair grade across different skin types and devices, suggesting a need for larger, more comprehensive trials.